Arcus Biosciences Inc
RCUS9.080USD
-0.080-0.87%
Market hours （ET）Quotes delayed by 15 min
961.57MMarket Cap
LossP/E TTM
More Details of Arcus Biosciences Inc Company
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company involves in a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Company Info
Ticker SymbolRCUS
Company nameArcus Biosciences Inc
IPO dateMar 15, 2018
CEODr. Terry J. Rosen, Ph.D.
Number of employees627
Security typeOrdinary Share
Fiscal year-endMar 15
Address3928 Point Eden Way
CityHAYWARD
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code94545-3719
Phone15106946200
Websitehttps://arcusbio.com/
Ticker SymbolRCUS
IPO dateMar 15, 2018
CEODr. Terry J. Rosen, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
Dr. Andrew Perlman, M.D., Ph.D.
Dr. Andrew Perlman, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Richard Markus, M.D., Ph.D.
Mr. Richard Markus, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Kathryn E. Falberg
Ms. Kathryn E. Falberg
Independent Director
Independent Director
--
--
Ms. Jennifer A. Jarrett
Ms. Jennifer A. Jarrett
Chief Operating Officer
Chief Operating Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Juan Carlos Jaen, Ph.D.
Dr. Juan Carlos Jaen, Ph.D.
President, Co-Founder
President, Co-Founder
1.44M
-0.15%
Dr. Yasunori Kaneko, M.D.
Dr. Yasunori Kaneko, M.D.
Lead Independent Director
Lead Independent Director
943.86K
+1.43%
Dr. David L. Lacey, M.D.
Dr. David L. Lacey, M.D.
Independent Director
Independent Director
62.55K
+27.00%
Dr. Antoni Ribas, M.D., Ph.D.
Dr. Antoni Ribas, M.D., Ph.D.
Independent Director
Independent Director
43.80K
+43.60%
Mr. Patrick Machado, J.D.
Mr. Patrick Machado, J.D.
Independent Director
Independent Director
30.20K
+78.70%
Mrs. Nicole Lambert
Mrs. Nicole Lambert
Independent Director
Independent Director
28.90K
+85.26%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
License and development services revenue
20.00M
71.43%
Collaboration revenue
8.00M
28.57%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
License and development services revenue
20.00M
71.43%
Collaboration revenue
8.00M
28.57%
Shareholding Stats
Updated: Sun, Jun 8
Updated: Sun, Jun 8
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
29.68%
BlackRock Institutional Trust Company, N.A.
9.14%
The Vanguard Group, Inc.
6.30%
Woodline Partners LP
4.84%
Fidelity Management & Research Company LLC
3.90%
Other
46.14%
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
29.68%
BlackRock Institutional Trust Company, N.A.
9.14%
The Vanguard Group, Inc.
6.30%
Woodline Partners LP
4.84%
Fidelity Management & Research Company LLC
3.90%
Other
46.14%
Shareholder Types
Shareholders
Proportion
Corporation
29.68%
Investment Advisor
27.66%
Hedge Fund
17.50%
Investment Advisor/Hedge Fund
12.68%
Individual Investor
5.36%
Venture Capital
2.82%
Research Firm
1.88%
Pension Fund
0.62%
Bank and Trust
0.29%
Other
1.52%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
438
104.36M
98.58%
+5.92M
2025Q1
461
106.23M
100.41%
+7.59M
2024Q4
458
92.45M
92.67%
-8.14M
2024Q3
459
92.17M
107.84%
+6.16M
2024Q2
456
90.82M
107.03%
+3.48M
2024Q1
456
91.60M
108.07%
-2.14M
2023Q4
455
76.21M
102.30%
-15.07M
2023Q3
450
76.35M
103.06%
-17.88M
2023Q2
441
78.29M
107.10%
-16.66M
2023Q1
448
78.22M
107.14%
-13.36M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences Inc
31.42M
29.68%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.68M
9.14%
+1.14M
+13.37%
Mar 31, 2025
The Vanguard Group, Inc.
6.68M
6.3%
+1.30M
+24.15%
Mar 31, 2025
Woodline Partners LP
5.13M
4.84%
+1.60M
+45.50%
Mar 31, 2025
Fidelity Management & Research Company LLC
4.12M
3.9%
+404.71K
+10.88%
Mar 31, 2025
State Street Global Advisors (US)
3.70M
3.49%
+702.75K
+23.47%
Mar 31, 2025
Point72 Asset Management, L.P.
2.87M
2.71%
+870.82K
+43.62%
Mar 31, 2025
Rosen Terry Jay
2.57M
2.43%
-472.90K
-15.53%
Mar 01, 2025
Suvretta Capital Management, LLC
2.56M
2.42%
+1.98M
+344.48%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.72M
1.63%
+19.78K
+1.16%
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
1.2%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
ALPS Medical Breakthroughs ETF
0.58%
Tema Oncology ETF
0.5%
Invesco S&P SmallCap Health Care ETF
0.39%
Invesco S&P SmallCap 600 Pure Growth ETF
0.31%
SPDR S&P Biotech ETF
0.2%
Direxion Daily S&P Biotech Bull 3X Shares
0.12%
Vanguard S&P Small-Cap 600 Growth Index Fund
0.08%
iShares S&P Small-Cap 600 Growth ETF
0.08%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion1.2%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.78%
ALPS Medical Breakthroughs ETF
Proportion0.58%
Tema Oncology ETF
Proportion0.5%
Invesco S&P SmallCap Health Care ETF
Proportion0.39%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion0.31%
SPDR S&P Biotech ETF
Proportion0.2%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.12%
Vanguard S&P Small-Cap 600 Growth Index Fund
Proportion0.08%
iShares S&P Small-Cap 600 Growth ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
